One Man Biotech Fund

So my team, four people including myself, is exploring the idea of starting a biotech portfolio that I would manage. Direct investments only. I am still pretty new to asset management (2nd year) and I'm a generalist although I do have a life science background.

I don't think this is feasible atm. For one, nobody else understands this stuff aside from me, so I have a really hard time explaining why it takes so long to evaluate companies in this space (can't expect me to come up with a buy/pass conclusion in three days, maybe a week depending on the opportunity...or am I just incompetent?). This brings me to the next problem, which is diversification. We are fairly concentrated, but I can't replicate this in biotech. From my initial calculations, I would need 25-35 positions. The worry here is the amount of time needed for accumulating this many positions. Assuming I reject at least 9 out of every 10 companies I review, I would have to run through at least 200-300 biotechs to come up with enough ideas. The most feasible option to me seems to be focusing on companies with products that already cleared phase 3, but where the share price remains depressed due to unproven execution know-how. 

I am considering excluding biotech altogether and instead adding medtech, services and the occasional big pharma that I can trust as a capital allocator.

Maybe I am wrong, maybe someone here has seen one-man shops delivering consistent returns in Biotech. Would love some perspective on how I could make this work.

1 Comments
 

Dolorum unde qui saepe ea non iure alias ut. Ipsum accusantium ea dolores ut. Sed aut nostrum excepturi aliquam ut. Sint optio nihil corporis sunt sequi cum voluptates cumque.

Et molestiae veritatis enim alias corrupti dolorem aut. Et ab eum quia earum et quia sapiente vel. Velit cum non voluptate laborum ab non minima vel. Molestiae dolor rerum consectetur nihil ad aut et at. Possimus ut eius libero.

Qui nemo aperiam voluptatem sed esse qui. Architecto consequatur qui hic inventore veniam provident iusto.

Career Advancement Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.8%
  • JPMorgan 01 98.2%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Morgan Stanley 02 98.8%
  • Evercore 01 98.2%
  • BMO Capital Markets 12 97.6%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.8%
  • Morgan Stanley 05 98.2%
  • JPMorgan No 97.7%
  • BMO Capital Markets 12 97.1%

Total Avg Compensation

June 2026 Investment Banking

  • Vice President (14) $434
  • Associates (43) $259
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (77) $151
  • Intern/Summer Analyst (71) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
kanon's picture
kanon
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
GameTheory's picture
GameTheory
98.9
6
dosk17's picture
dosk17
98.9
7
Betsy Massar's picture
Betsy Massar
98.9
8
DrApeman's picture
DrApeman
98.9
9
CompBanker's picture
CompBanker
98.9
10
Jamoldo's picture
Jamoldo
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”